Muthiah Vaduganathan
#125,552
Most Influential Person Now
Researcher
Muthiah Vaduganathan's AcademicInfluence.com Rankings
Muthiah Vaduganathanmedical Degrees
Medical
#1998
World Rank
#2387
Historical Rank
Cardiology
#165
World Rank
#170
Historical Rank
Public Health
#281
World Rank
#292
Historical Rank
Epidemiology
#333
World Rank
#350
Historical Rank
Muthiah Vaduganathanphilosophy Degrees
Philosophy
#5874
World Rank
#8797
Historical Rank
Logic
#3083
World Rank
#4191
Historical Rank
Download Badge
Medical Philosophy
Muthiah Vaduganathan's Degrees
- Doctorate Medicine Harvard University
Why Is Muthiah Vaduganathan Influential?
(Suggest an Edit or Addition)Muthiah Vaduganathan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (5789)
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (3308)
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 (2020) (2362)
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 (2020) (1664)
- The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. (2014) (1566)
- Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (1515)
- Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2019) (1485)
- Rehospitalization for heart failure: problems and perspectives. (2013) (608)
- Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (538)
- Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. (2008) (319)
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials (2020) (267)
- Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction: The ARIC Community Surveillance Study (2019) (259)
- Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure (2019) (250)
- Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. (2019) (246)
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. (2022) (225)
- The vulnerable phase after hospitalization for heart failure (2015) (200)
- Mode of Death in Heart Failure With Preserved Ejection Fraction. (2017) (178)
- Clinical Outcomes in Young US Adults Hospitalized With COVID-19. (2020) (165)
- Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial (2012) (160)
- Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment (2018) (150)
- Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic (2020) (137)
- Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes (2020) (135)
- Haemoconcentration, renal function, and post‐discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial (2013) (124)
- Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review (2018) (124)
- Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score (2019) (120)
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction (2013) (118)
- Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017 (2020) (116)
- B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. (2019) (115)
- Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. (2019) (115)
- Thirty-day readmissions: the clock is ticking. (2013) (114)
- The rise and fall of aspirin in the primary prevention of cardiovascular disease (2019) (114)
- Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro (2010) (113)
- Declines in Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic: A Multicenter Tertiary Care Experience (2020) (111)
- Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides (2017) (109)
- Oral Anticoagulation in Patients With Liver Disease. (2018) (106)
- Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. (2001) (104)
- Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. (2020) (103)
- Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. (2018) (95)
- Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. (2019) (93)
- The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. (2014) (92)
- Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. (2019) (92)
- Midterm survival in patients treated for atrial fibrillation: a propensity-matched comparison to patients without a history of atrial fibrillation. (2012) (91)
- Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic (2020) (88)
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. (2018) (86)
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials (2022) (86)
- Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. (2013) (86)
- Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19 (2020) (84)
- Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use (2015) (84)
- Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. (2014) (81)
- Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights from the EVEREST Trial (2012) (78)
- The disconnect between phase II and phase III trials of drugs for heart failure (2013) (77)
- The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. (2013) (75)
- Serum protein signatures detect early radiographic osteoarthritis. (2009) (74)
- Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association (2020) (73)
- Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF. (2019) (72)
- Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. (2019) (70)
- Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review (2016) (69)
- Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. (2016) (69)
- Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week. (2020) (67)
- Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. (2019) (67)
- Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy (2019) (65)
- Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs. (2019) (64)
- A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial (2019) (62)
- Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. (2008) (61)
- Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. (2013) (61)
- Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure (2013) (61)
- The Drug-Intoxication Epidemic and Solid-Organ Transplantation. (2018) (58)
- Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. (2019) (58)
- Left Ventricular Thrombus: Contemporary Etiologies, Treatment Strategies, and Outcomes. (2019) (58)
- Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). (2014) (57)
- Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. (2020) (56)
- Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions (2014) (56)
- Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients with Heart Failure and Reduced Ejection Fraction:PARADIGM-HF. (2019) (55)
- The immunological axis in heart failure: importance of the leukocyte differential (2013) (55)
- Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. (2020) (54)
- Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. (2020) (53)
- Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges (2018) (52)
- Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta‐analysis (2020) (52)
- Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. (2018) (52)
- Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. (2020) (51)
- Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2013) (49)
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis (2020) (49)
- Type 2 Myocardial Infarction—Diagnosis, Prognosis, and Treatment (2018) (48)
- Kidney Function and Outcomes in Patients Hospitalized with Heart Failure. (2021) (48)
- Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics (2017) (48)
- Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial (2021) (48)
- Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. (2020) (48)
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. (2018) (48)
- Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives. (2013) (47)
- Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden) (2021) (47)
- Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. (2022) (47)
- Hemoconcentration-guided diuresis in heart failure. (2014) (46)
- Relation of body mass index to late survival after valvular heart surgery. (2012) (44)
- Trends in prevalence of comorbidities in heart failure clinical trials (2020) (43)
- Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. (2020) (42)
- Prognostic scores in heart failure - Critical appraisal and practical use. (2015) (42)
- Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. (2021) (41)
- Postmarketing Adverse Events Related to the CardioMEMS HF System (2017) (41)
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
- Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. (2018) (40)
- Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER (2022) (39)
- Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). (2015) (39)
- Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis (2017) (38)
- Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. (2014) (38)
- Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials (2020) (38)
- Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials (2017) (38)
- Immune‐related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia (2017) (37)
- Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. (2020) (37)
- Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. (2020) (37)
- Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. (2019) (36)
- Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. (2016) (36)
- Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. (2016) (36)
- Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Findings From the EVEREST Trial (2014) (35)
- Association of the New Peer Group–Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program (2019) (35)
- Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. (2020) (35)
- Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. (2017) (34)
- Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure (2020) (34)
- Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment (2012) (34)
- Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. (2020) (34)
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. (2020) (34)
- Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial (2018) (34)
- Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. (2017) (34)
- Global Health Educational Engagement—A Tale of Two Models (2013) (33)
- A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction (2020) (33)
- Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. (2021) (33)
- Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis (2019) (32)
- Natriuretic peptide-guided management in heart failure (2016) (32)
- Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 (2021) (31)
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. (2019) (31)
- ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization (2021) (31)
- Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. (2015) (31)
- Water and Sodium in Heart Failure: A Spotlight on Congestion (2014) (31)
- Moving Toward Global Primordial Prevention in Cardiovascular Disease: The Heart of the Matter. (2015) (30)
- Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction (2021) (30)
- Anticoagulation in heart failure: current status and future direction (2013) (29)
- Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals (2018) (29)
- The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers (2015) (29)
- Pre‐discharge and early post‐discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial (2018) (29)
- Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. (2019) (28)
- Antihyperglycemic Therapies with Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns within an Academic Medical Center. (2020) (28)
- Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. (2019) (28)
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. (2020) (28)
- Conduct of Clinical Trials in the Era of COVID-19 (2020) (28)
- Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. (2018) (27)
- Distribution of Alkaline Phosphatase, Osteopontin, RANK Ligand and Osteoprotegerin in Calcified Human Carotid Atheroma (2015) (27)
- Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis (2020) (27)
- Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations (2013) (27)
- Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. (2020) (27)
- Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. (2017) (26)
- Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. (2019) (26)
- Fifteen‐Year Trends in Management and Outcomes of Non–ST‐Segment–Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000–2014 (2018) (26)
- Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial (2020) (25)
- Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study (2021) (25)
- Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction (2014) (25)
- Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions (2018) (25)
- Increased platelet sensitivity among individuals with aspirin resistance – Platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy (2008) (25)
- Trends in Heart Failure Clinical Trials From 2001-2012. (2016) (25)
- Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. (2007) (24)
- In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. (2021) (24)
- Angioedema in COVID-19 (2020) (24)
- The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry (2013) (24)
- Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. (2012) (24)
- Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. (2010) (24)
- High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network (2018) (23)
- Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. (2019) (23)
- The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. (2022) (23)
- Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. (2017) (23)
- Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. (2020) (23)
- Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. (2018) (23)
- Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? (2016) (23)
- Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. (2016) (22)
- Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). (2020) (21)
- Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. (2019) (21)
- Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. (2017) (21)
- Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial (2020) (21)
- Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016 (2020) (21)
- Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure: The ARIC Study. (2020) (21)
- Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes (2015) (21)
- Influence of atrial fibrillation on post‐discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial (2017) (21)
- Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. (2019) (21)
- Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial (2016) (20)
- Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency (2019) (20)
- Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems. (2018) (20)
- Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial (2013) (20)
- Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. (2019) (19)
- Incidence and Outcomes of Pneumonia in Patients With Heart Failure. (2021) (19)
- Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. (2017) (19)
- Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery (2007) (19)
- Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience. (2017) (19)
- Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017 (2021) (19)
- Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF (2022) (19)
- Association between depression and readmission of heart failure: A national representative database study. (2020) (18)
- Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk (2021) (18)
- Cardiovascular and Kidney Outcomes across the Glycemic Spectrum: Insights from the UK Biobank. (2021) (17)
- Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. (2016) (17)
- Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. (2018) (17)
- Mobile health applications in cardiovascular research. (2018) (17)
- Incidence, predictors, and outcomes of failed primary percutaneous coronary intervention: a 10-year contemporary experience (2014) (17)
- Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. (2020) (17)
- Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes (2014) (17)
- Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event (2017) (17)
- Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. (2022) (17)
- Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). (2019) (17)
- Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial (2016) (16)
- Comparison of late (3-year) registry data outcomes using bare metal versus drug-eluting stents for treating ST-segment elevation acute myocardial infarctions. (2012) (16)
- Drug therapy to reduce early readmission risk in heart failure: ready for prime time? (2013) (16)
- Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map (2021) (16)
- Site selection for heart failure clinical trials in the USA (2015) (16)
- Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial (2022) (16)
- Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. (2020) (16)
- Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients (2021) (16)
- Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial (2017) (16)
- Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial (2021) (16)
- Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. (2022) (15)
- Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. (2020) (15)
- Trends in Female Authorship: A Bibliometric Analysis of the Annals of Thoracic Surgery. (2020) (15)
- A Triad of Linezolid Toxicity: Hypoglycemia, Lactic Acidosis, and Acute Pancreatitis (2015) (15)
- Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2012) (15)
- Optimizing Foundational Therapies in Patients With HFrEF (2022) (15)
- Open Access Publishing and Subsequent Citations Among Articles in Major Cardiovascular Journals. (2019) (15)
- Prevalence of Apparent Treatment‐Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline (2019) (15)
- Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. (2013) (15)
- Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis (2020) (15)
- Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial (2015) (15)
- Trends in Hospitalizations for Heart Failure, Acute Myocardial Infarction, and Stroke in the United States from 2004-2018. (2021) (14)
- Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial (2022) (14)
- Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. (2016) (14)
- Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. (2019) (14)
- Implications of Specialist Density for Diabetes Care in the United States. (2019) (13)
- Clopidogrel response up to six months after acute myocardial infarction. (2012) (13)
- DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases (2021) (13)
- Relation of aspirin response to age in patients with stable coronary artery disease. (2013) (13)
- Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. (2021) (13)
- Application of the H2FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial (2019) (13)
- Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy (2020) (13)
- Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction (2022) (12)
- APPLICATION OF THE H2FPEF-SCORE TO A GLOBAL CLINICAL TRIAL OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE TOPCAT TRIAL (2019) (12)
- Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years (2018) (12)
- Platelet reactivity among Asian Indians and Caucasians (2007) (12)
- Availability and Use of Shared Data From Cardiometabolic Clinical Trials (2017) (12)
- Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). (2017) (12)
- Epidemiologic characterization of heart failure with reduced or preserved ejection fraction populations identified using Medicare claims. (2020) (12)
- Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT (2017) (12)
- Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure (2022) (11)
- Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. (2020) (11)
- Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. (2018) (11)
- Death due to munchausen syndrome: a case of idiopathic recurrent right ventricular failure and a review of the literature. (2014) (11)
- Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19 (2021) (11)
- Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. (2019) (11)
- Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia (2021) (11)
- Cardiologist Evaluation of Patients with Type 2 Myocardial Infarction. (2020) (11)
- Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography (2020) (11)
- Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. (2022) (11)
- Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes (2021) (11)
- Serum chloride in heart failure: a salty prognosis (2016) (11)
- Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). (2019) (11)
- Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. (2020) (11)
- Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? (2019) (11)
- Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. (2022) (11)
- Biomarker Profile of Left Atrial Myopathy in Heart Failure with Preserved Ejection Fraction: Insights from the RELAX Trial. (2019) (11)
- Nomenclature in heart failure: a call for objective, reproducible, and biologically‐driven terminology (2018) (11)
- Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials (2022) (10)
- Angiotensin receptor–neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON‐HF (2020) (10)
- Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. (2021) (10)
- Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. (2017) (10)
- Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction (2020) (10)
- Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists (2015) (10)
- Emerging Trends in Financing of Adult Heart Transplantation in the United States. (2019) (10)
- Organ Donation and Drug Intoxication-Related Deaths in the United States. (2019) (10)
- Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction. (2013) (10)
- Retroperitoneal Bleeding after Cardiac Catheterization: A 7-Year Descriptive Single-Center Experience (2013) (10)
- Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. (2021) (10)
- Association of Medicaid Expansion with Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. (2020) (9)
- Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF (2022) (9)
- Running thin: implications of a heparin shortage (2020) (9)
- Midterm benefits of preoperative statin therapy in patients undergoing isolated valve surgery. (2012) (9)
- Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. (2019) (9)
- Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents (2011) (9)
- Impact of the COVID-19 Pandemic on Cardiovascular Health in 2020 (2022) (9)
- Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration (2019) (9)
- Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency (2020) (9)
- Training the Next Generation of Cardiometabolic Specialists. (2020) (9)
- History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. (2019) (9)
- Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial (2022) (9)
- Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). (2013) (9)
- Gender differences in industry payments among cardiologists. (2019) (9)
- Critical reappraisal of pulmonary artery catheterization and invasive hemodynamic assessment in acute heart failure (2013) (9)
- On the Cusp. (2017) (8)
- Integrating electronic health records into the study of heart failure: promises and pitfalls (2017) (8)
- Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads (2016) (8)
- Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. (2017) (8)
- Midlife Wealth Mobility and Long-term Cardiovascular Health. (2021) (8)
- Sex Differences in Patient Characteristics, Treatment Strategies, and Outcomes for Type 2 Myocardial Infarction. (2019) (8)
- Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial (2022) (8)
- Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial (2021) (8)
- SUDDEN DEATH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A COMPETING RISKS ANALYSIS FROM THE TOPCAT TRIAL (2018) (8)
- Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. (2021) (8)
- Metastatic Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropic Hormone Production (2015) (8)
- Large-Volume Barium Aspiration (2015) (8)
- Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). (2014) (8)
- Angiotensin-Neprilysin Inhibition as a Paradigm for All? (2016) (8)
- Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response (2015) (8)
- Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study (2019) (7)
- Dapagliflozin for heart failure according to body mass index: the DELIVER trial (2022) (7)
- Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction. (2019) (7)
- Cardio-Renal-Metabolic Care Models (2020) (7)
- Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard (2019) (7)
- Expanded algorithm for managing patients with acute decompensated heart failure (2018) (7)
- Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure (2018) (7)
- CONTEMPORARY ETIOLOGIES, TREATMENT STRATEGIES, AND OUTCOMES OF LEFT VENTRICULAR THROMBUS (2019) (7)
- Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries (2020) (7)
- Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. (2021) (7)
- Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population‐based cohort study of >25 000 Medicare beneficiaries (2022) (7)
- Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. (2018) (7)
- Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. (2017) (7)
- Elevated Troponin Levels in Stable Patients Undergoing Hemodialysis: A Red Flag or a Red Herring? (2016) (7)
- Contemporary parenteral antiplatelet bridging strategies: a single-centre real-world experience at a tertiary care centre. (2018) (7)
- Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial (2021) (7)
- Application of the GRACE, TIMI, and TARRACO Risk Scores in Type 2 Myocardial Infarction. (2019) (7)
- Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment (2018) (7)
- SGLT-2 inhibitors in heart failure: a new therapeutic avenue (2019) (7)
- Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. (2020) (7)
- Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis (2021) (7)
- Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? (2016) (7)
- Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure (2020) (6)
- Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). (2019) (6)
- Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. (2020) (6)
- Modern drug development: which patients should come first? (2014) (6)
- Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes (2021) (6)
- Educating the Next Generation of Peer Reviewers. (2016) (6)
- Contemporary economic burden in a real‐world heart failure population with Commercial and Medicare supplemental plans (2021) (6)
- Thirty-Day Non-Index Readmissions and Clinical Outcomes Following Cardiac Surgery. (2020) (6)
- Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). (2018) (6)
- Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction (2022) (6)
- Predictors of High Impact Articles in The Annals of Thoracic Surgery. (2020) (6)
- Medicaid Expansion and Utilization of Antihyperglycemic Therapies (2020) (6)
- Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack (2021) (6)
- Aspirin and proton-pump inhibitors: interpreting the interplay. (2016) (6)
- Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling (2022) (6)
- Sunday, 26 August 2012 (2012) (5)
- Extensive Arterial Thrombosis in Covid-19 (2020) (5)
- Intravenous moderate-dose bumetanide continuous infusion and severe musculoskeletal pain. (2013) (5)
- The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. (2017) (5)
- Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction (2020) (5)
- Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial (2022) (5)
- Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials (2020) (5)
- Estimating the Benefits of Combination Medical Therapy in Heart Failure with Mildly Reduced and Preserved Ejection Fraction. (2022) (5)
- Marijuana Use in Patients With Cardiovascular€Disease (5)
- Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate (2022) (5)
- Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. Reply. (2020) (5)
- Developing evidence‐based and accountable health policy in heart failure (2018) (5)
- Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure (2021) (5)
- Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care (2021) (5)
- Epirubicin and long‐term heart failure risk in breast cancer survivors (2018) (5)
- Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization (2016) (5)
- Anticoagulation Strategies in Patients With Cancer (2019) (5)
- Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One? (2016) (5)
- Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. (2022) (5)
- A "Malignant" Arrhythmia: Cardiac Metastasis and Ventricular Tachycardia. (2016) (5)
- Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure. (2020) (5)
- Expanding the scope of the "polypill" to heart failure. (2013) (5)
- Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials (2022) (5)
- Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials (2021) (5)
- Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. (2022) (5)
- Glucose-Lowering Therapies in Patients With Concomitant Diabetes Mellitus and Heart Failure: Finding the "Sweet Spot". (2018) (4)
- Marijuana Use and In-Hospital Outcomes After Percutaneous Coronary Intervention in Michigan, United States. (2021) (4)
- Home‐Time After Discharge Among Patients With Type 2 Myocardial Infarction (2020) (4)
- Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. (2022) (4)
- Preparing Fellows for Precision Cardiology: Are We Ready? (2017) (4)
- Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors over Time in Heart Failure with Reduced Ejection Fraction. (2021) (4)
- Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. (2021) (4)
- Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. (2021) (4)
- Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States (2021) (4)
- Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans’ Health Administrative Database (2021) (4)
- What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure? (2020) (4)
- Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306 (2020) (4)
- Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with a History of Bariatric Surgery. (2021) (4)
- Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure (2022) (4)
- Screening and Management of Depression in Patients with Cardiovascular Disease (2019) (4)
- Reappraisal of the safety and effectiveness of Impella pumps (2020) (4)
- Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018 (2022) (4)
- Wake Forest University long‐term follow‐up of type 2 myocardial infarction: The Wake‐Up T2MI Registry (2019) (4)
- Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF (2021) (4)
- Lipids, statins, and clinical outcomes in heart failure: rethinking the data (2014) (4)
- Expanding the global borders of heart failure: the SHOP and PEOPLE studies (2018) (4)
- Natriuretic peptide-guided management in heart failure. (2015) (4)
- Accelerated and personalized therapy for heart failure with reduced ejection fraction. (2022) (4)
- The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience. (2020) (4)
- Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7 year nationwide veteran administration analysis. (2021) (4)
- Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (2022) (4)
- How Do SGLT-2 Inhibitors Work to Prevent Heart Failure? (2020) (4)
- Revisiting the Clopidogrel-Proton Pump Inhibitor Interaction: From Bench to Bedside. (2015) (4)
- Cardiac Troponins in Chronic Kidney Disease: A Marker of Global Cardiovascular Risk (2017) (4)
- Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. (2019) (4)
- Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. (2022) (3)
- Physician Practice Pattern Variations in Common Clinical Scenarios Within 5 US Metropolitan Areas (2022) (3)
- Post‐discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial (2019) (3)
- HOME-TIME AFTER DISCHARGE AMONG PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION (2020) (3)
- Thirty-Day Readmissions (2017) (3)
- Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. (2020) (3)
- Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. (2022) (3)
- Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019 (2020) (3)
- Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials. (2021) (3)
- Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). (2015) (3)
- Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations (2015) (3)
- Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure (2022) (3)
- Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF (2022) (3)
- Roadmap to inpatient heart failure management. (2015) (3)
- Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials (2017) (3)
- Citizenship Status and Cardiothoracic Organ Transplantation in the United States. (2020) (3)
- SGLT-2 Inhibitors in Heart Failure: Volume or Value? (2021) (3)
- Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance (2021) (3)
- Guideline based eligibility for primary prevention statin therapy - Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). (2021) (3)
- Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. (2019) (3)
- Progress or lack of progress in hospitalized heart failure (2013) (3)
- Health Status Trajectories Before and After Hospitalization for Heart Failure. (2022) (3)
- Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes (2022) (3)
- Monday, 27 August 2012 (2012) (3)
- Return of digoxin and recovery of renal function. (2013) (3)
- Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT) (2021) (3)
- Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. (2015) (3)
- Torus Palatinus (2014) (3)
- Gender Differences in Medicare Payments Among Cardiologists. (2021) (3)
- Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. (2021) (3)
- Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach (2022) (3)
- Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial (2022) (3)
- Longitudinal Trajectories of Hospital Performance across Targeted Cardiovascular Conditions in the United States. (2019) (3)
- Manual Thrombectomy in Myocardial Infarction: Aspiring for Better (2015) (3)
- Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy? (2014) (3)
- Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines‐Heart Failure Registry (2022) (3)
- Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019 (2021) (3)
- IMAGES IN CLINICAL MEDICINE. Ping-Pong Gaze. (2015) (3)
- Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. (2022) (3)
- Assessment of Heterogeneity in Heart Failure–Related Meta-Analyses (2020) (3)
- The Relationship Between Atrial Fibrillation, Mitral Regurgitation, and Heart Failure Subtype: The ARIC Study (2021) (2)
- One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). (2016) (2)
- Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. (2020) (2)
- Association of Baseline and Longitudinal Changes in Frailty Burden and Risk of Heart Failure in Type 2 Diabetes - Findings from the Look AHEAD Trial. (2022) (2)
- Endpoints for diuresis: are we there yet? (2014) (2)
- Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. (2022) (2)
- Virtual Care Team-Guided Therapeutic Optimization During Hospitalization in Patients with Heart Failure: The IMPLEMENT-HF Study. (2023) (2)
- Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan (2022) (2)
- The Use of Circulatory Support While Awaiting Heart Transplant in Patients With AL and TTR: Amyloidosis: A Report From iCCAT, the International Consortium for Cardiac Amyloid Transplant (2015) (2)
- INFLUENCE OF AGE ON EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (2020) (2)
- Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. (2022) (2)
- Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout (2023) (2)
- LONGITUDINAL CHANGES IN MEDICATION DOSING AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: FROM THE CHAMP-HF REGISTRY (2019) (2)
- Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic (2021) (2)
- Manual Thrombectomy in Myocardial Infarction: Aspiring for Better. (2015) (2)
- Adoption of hepatitis C virus-infected donor hearts: A "middle child" no more. (2019) (2)
- Premature Ticagrelor Discontinuation inSecondary Prevention of AtheroscleroticCVD (2019) (2)
- Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial (2023) (2)
- De novo heart failure: where the journey begins (2019) (2)
- Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. (2021) (2)
- Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States (2021) (2)
- Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- a report from the Atherosclerosis Risk in Communities (ARIC) study. (2022) (2)
- Gastroprotection with proton-pump inhibitors in high-risk cardiovascular patients: who to target and for how long? (2016) (2)
- Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. (2022) (2)
- Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure (2019) (2)
- Contemporary Trends in the Use of and Expenditures on Digoxin in the United States (2022) (2)
- Angiotensin–neprilysin inhibition in de novo heart failure – starting off strong (2019) (2)
- Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake (NUDGE-FLU): Study Protocol for a Nationwide Randomized Implementation Trial. (2023) (2)
- Investigating the Association Between Telemedicine Use and Timely Follow-Up Care After Acute Cardiovascular Hospital Encounters (2022) (2)
- Validation of the WATCH‐DM and TRS‐HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis (2022) (2)
- Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER (2022) (2)
- PROTON-PUMP INHIBITORS REDUCE RISK OF GASTROINTESTINAL EVENTS REGARDLESS OF ASPIRIN DOSE IN PATIENTS REQUIRING DUAL ANTIPLATELET THERAPY: INSIGHTS FROM THE COGENT TRIAL (2016) (2)
- Stroke prevention in heart failure and sinus rhythm: where do we go from here? (2016) (2)
- Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction (2017) (2)
- Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: The Systolic Blood Pressure Intervention Trial (SPRINT). (2020) (2)
- Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. (2016) (2)
- Classification of patients hospitalized for heart failure. (2013) (2)
- Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. (2020) (2)
- Nine contemporary therapeutic directions in heart failure (2019) (2)
- Uremic Pericarditis: Distinguishing Features in a Now-Uncommon Clinical Syndrome. (2018) (2)
- Transforming the interpretation of significance in heart failure trials (2019) (2)
- Intensive versus standard blood pressure control and vascular procedures: Insights from the Systolic Blood Pressure Intervention Trial (SPRINT). (2020) (2)
- Health‐related quality of life outcomes in PARAGON‐HF (2022) (2)
- Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design. (2021) (2)
- Assessing the Quality of Reporting of Harms in Randomized Controlled Trials Published in High Impact Cardiovascular Journals. (2019) (2)
- Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. (2022) (2)
- Abstract 13760: Intensive versus Standard Blood Pressure Control in Patients With Peripheral Artery Disease: The Systolic Blood Pressure Intervention Trial (SPRINT) (2020) (2)
- Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial (2018) (2)
- Eligibility for SGLT2 Inhibitors in Heart Failure Without the Race Coefficient for Kidney Function Estimation. (2021) (2)
- Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction (2021) (2)
- Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. (2020) (2)
- Prioritizing Dissemination and Implementation Science in Cardiometabolic Medicine: CONNECTing the Dots. (2021) (2)
- CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN – INSIGHTS FROM CHAMPION PHOENIX (2017) (1)
- Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. (2022) (1)
- Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction (2022) (1)
- Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance (2021) (1)
- TRENDS IN RACIAL DIFFERENCES IN 30-DAY READMISSION RATE FOR ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE NCDR CHEST PAIN-MI REGISTRY (2019) (1)
- Dual antiplatelet therapy after stent implantation. (2014) (1)
- Collaborative Care in an Evolving Health Care Delivery Landscape: Cardiology Fellows in Training and Advanced Practice Professionals. (2017) (1)
- Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors (2019) (1)
- Trends, Management, and Outcomes of Acute Myocardial Infarction Hospitalizations With In‐Hospital‐Onset Versus Out‐of‐Hospital Onset: The ARIC Study (2021) (1)
- 418Pulse pressure and cardiovascular outcomes in high-risk individuals enrolled in the Systolic Blood Pressure Intervention Trial (SPRINT) (2018) (1)
- Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. (2023) (1)
- NT-PROBNP, LEFT VENTRICULAR STRUCTURE AND FUNCTION, AND LONG-TERM CARDIOVASCULAR EVENTS: INSIGHTS FROM A PROSPECTIVE POPULATION-BASED COHORT STUDY (2017) (1)
- Sudden Death Following Hospitalization for Heart Failure with Reduced Ejection Fraction (From the EVEREST Trial) (2018) (1)
- Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial (2022) (1)
- Marijuana Use in Patients with Cardiovascular Disease: Current Knowledge and Gaps (2021) (1)
- Serial troponin-T and long-term outcomes in suspected acute coronary syndrome. (2022) (1)
- MODIFIED BMI DOES NOT PREDICT ADVERSE OUTCOMES IN PATIENTS WITH CARDIAC AMYLOID UNDERGOING HEART TRANSPLANTATION: A REPORT FROM ICCAT (INTERNATIONAL CONSORTIUM FOR CARDIAC AMYLOID TRANSPLANTATION) (2015) (1)
- CLINICAL PROFILES, MEDICAL THERAPIES, AND OUTCOMES AMONG PATIENTS HOSPITALIZED FOR HF ACROSS THE SPECTRUM OF KIDNEY FUNCTION: THE GWTG-HF REGISTRY (2021) (1)
- Coronary stenting approaches in the treatment of chronic total occlusion: contemporary registry-based experience (2016) (1)
- MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND LEFT VENTRICULAR EJECTION FRACTION≥45%: INSIGHTS FROM PARAGON-HF (2020) (1)
- Abstract 20769: Sudden Cardiac Death Risk After Hospitalization for Heart Failure: Insights From EVEREST (2017) (1)
- Circulating ketone bodies and cardiovascular outcomes: the MESA study. (2023) (1)
- Heads Up! Introducing Wearable Health Technologies in Cardiology. (2015) (1)
- Abstract 14700: Twenty Year Trends and Sex Differences in Young Adults With Acute Myocardial Infarction: The ARIC Community Surveillance Study (2018) (1)
- Orphan Drug Development in Cardiovascular Medicine (2020) (1)
- Serum Potassium and Mortality in High-Risk Patients: SPRINT (2021) (1)
- Expanding the Scope of Multimodality Imaging in Durable Mechanical Circulatory Support. (2020) (1)
- Influence of Age on the Efficacy and Safety of Spironolactone in Heart Failure with Preserved Ejection Fraction (2019) (1)
- Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches (2020) (1)
- Unintended Impact of US Food and Drug Administration Recalls on the Use of Contaminated and Non-Contaminated Angiotensin Receptor Blockers Among Medicaid Beneficiaries (2019) (1)
- Building a Curriculum for the Cardiovascular Implementation Scientist. (2022) (1)
- Endothelin Receptor Antagonists and Risk of Heart Failure in CKD: Balancing the Cardiorenal Axis. (2022) (1)
- Patient-Reported Outcome Measures in Cardiovascular Disease: An Evidence Map of the Psychometric Properties of Health Status Instruments (2022) (1)
- Immortal person-time bias in observational studies in cardiac surgery. (2011) (1)
- Estimated Event-Free Survival Benefits with Dapagliflozin in HF with Mildly Reduced or Preserved Ejection Fraction. (2022) (1)
- Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). (2021) (1)
- Acute Lymphocytic Leukemia with Superimposed Invasive Aspergillosis and Pneumopericardium Successfully Treated with Voriconazole (2014) (1)
- OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure (2021) (1)
- 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME (2020) (1)
- Neprilysin and Corin: It Takes Two to Tango. (2020) (1)
- Medication-Attributable Adverse Events in Heart Failure Trials. (2023) (1)
- Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. (2022) (1)
- Risk of Acute Kidney Injury among Older Adults with Heart Failure with Reduced Ejection Fraction Treated with Angiotensin-Neprilysin Inhibitor Versus Renin-Angiotensin System Inhibitor in Routine Clinical Care. (2022) (1)
- Moving Beyond the Hospital. (2018) (1)
- Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial (2022) (1)
- Simultaneous Platelet P2Y 12 and P2Y 1 ADP Receptor Blockade (2016) (1)
- Abstract P320: Temporal Trends In Prevalence & Prognostic Implications Of Cardiac And Non-cardiac Comorbidities Among Patients With Acute Decompensated Heart Failure: Aric Study Community Surveillance (2020) (1)
- Abstract 17007: Racial Trends in Angiographic Evaluation and Revascularization for Non-ST Segment Myocardial Infarction: The Atherosclerosis Risk in Communities Surveillance Study (2017) (1)
- Abstract 14373: Efficacy and Safety of Antihypertensive Drug Classes: The Systolic Blood Pressure Intervention Trial (SPRINT) (2020) (1)
- Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope. (2018) (1)
- Medication burden in older patients with heart failure: a cohort study of Medicare beneficiaries. (2020) (1)
- Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. (2023) (1)
- Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. (2018) (1)
- Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients with Heart Failure. (2023) (1)
- Missense Genetic Variation of ICAM1 and Incident Heart Failure. (2023) (1)
- Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream? (2018) (1)
- The Intersection of Type 2 Myocardial Infarction and Heart Failure. (2021) (1)
- Dapagliflozin in Heart Failure with Preserved Ejection Fraction. Reply. (2023) (1)
- Abstract 12886: In-hospital and Early Post-discharge Troponin Elevations Among Patients Hospitalized for Heart Failure: Insights From the ASTRONAUT Trial (2016) (1)
- COST-EFFECTIVENESS OF MEDICAL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (2023) (0)
- Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT) (2020) (0)
- Abstract P131: Optimal Phenomapping Strategy to Identify Novel Subgroups of Patients With Type 2 Diabetes and High Cardiovascular Disease Risk (2020) (0)
- GEOGRAPHICAL VARIATION IN PATIENT CHARACTERISTICS AND OUTCOMES IN HFPEF (2023) (0)
- 0.050). The relative and absolute bene fi ts of sacubitril/valsartan compared with valsartan alone in heart failure with preserved ejection fraction appear to be ampli fi ed when initiated in the high-risk window after hospitalization and warrants prospe (2020) (0)
- The perils of long surgical experiences: changes in case mix over time. (2013) (0)
- MACHINE LEARNING TO IDENTIFY HIGH-RISK PATIENTS AFTER STEMI IN LOW/MIDDLE INCOME COUNTRIES (2021) (0)
- EFFECT OF SACUBITRIL/VALSARTAN VS. ENALAPRIL ON CHANGES IN BACKGROUND MEDICAL THERAPY OVER TIME IN THE PARADIGM-HF TRIAL (2020) (0)
- INFLUENZA VACCINATION TRENDS IN PATIENTS WITH HEART FAILURE BY EJECTION FRACTION (2020) (0)
- Prevalence and prognostic implications of reduced left ventricular ejection fraction among patients with STEMI in India (2022) (0)
- Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. (2023) (0)
- Epidemiology and Outcomes of Aortic Stenosis in Acute Decompensated Heart Failure: The ARIC Study (2023) (0)
- TRENDS IN UTILIZATION OF GENERIC AND BRAND-NAME LDL-LOWERING PRESCRIPTION DRUGS AMONG MEDICARE PART D BENEFICIARIES BETWEEN 2013 AND 2017 (2020) (0)
- Abstract 16940: Missed Opportunities for Screening and Management of Dysglycemia After Myocardial Infarction: The Prospective NORIN STEMI Registry (2020) (0)
- Picking Up the Torch (2020) (0)
- Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System. (2022) (0)
- Closer to FREEDOM From Uncertainty (2023) (0)
- Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock. (2017) (0)
- Benefit of Longitudinal Pulmonary Artery Pressure Monitoring to Reduce Heart Failure Hospitalization Extends to Obese Patients (2016) (0)
- Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT) (2020) (0)
- Abstract 13945: Omega-3 Fatty Acids, Triglyceride Concentrations, and Cardiovascular Outcomes: The Systolic Blood Pressure Intervention Trial (SPRINT) (2020) (0)
- THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS (2016) (0)
- Abstract 17027: Generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry (2020) (0)
- Abstract P319: Racial Differences and Temporal Trends in Obesity Among Patients Hospitalized With Acute Decompensated Heart Failure With Preserved Ejection Fraction: The ARIC Study Community Surveillance (2020) (0)
- The Reply. (2018) (0)
- A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study (2023) (0)
- Implementation of Cardiometabolic Centers and Training Programs (2022) (0)
- Erratum to: The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers (2015) (0)
- Chapter-06 Hospitalization for Heart Failure: Pathophysiology, Classification, and Management Considerations (2014) (0)
- Addressing Equity and More in 2021 (2021) (0)
- TRENDS IN UTILIZATION OF SURROGATE ENDPOINTS IN CONTEMPORARY CARDIOVASCULAR CLINICAL TRIALS: A SYSTEMATIC REVIEW (2016) (0)
- Reply: To PMID 23219302. (2013) (0)
- HEART FAILURE EVENTS AFTER TYPE 2 MYOCARDIAL INFARCTION (2020) (0)
- 1090-P: Prevalence of Diabetic Cardiomyopathy in an Electronic Health Record–Based Cohort (2022) (0)
- A Heart Team approach to contemporary device decision‐making in heart failure (2022) (0)
- HEART FAILURE HOSPITALIZATIONS AND URGENT HEART FAILURE VISITS FOR PATIENTS WITH HEART FAILURE IN A REAL-WORLD POPULATION IN THE US (2020) (0)
- Myocardial Infarction Response to Prasugrel and Levels of Circulating Reticulated Platelets in Patients With ST-Segment Elevation Myocardial Infarction (0)
- Abstract 17134: Biomarker-Based Risk Prediction of Incident Heart Failure Over 5 Years in Prediabetes and Diabetes: Pooled Analysis Across 3 US Community Cohorts (2020) (0)
- CARDIOVASCULAR AND RENAL OUTCOMES ACROSS THE GLYCEMIC SPECTRUM: INSIGHTS FROM THE UK BIOBANK (0)
- MIDTERM BENEFITS OF PERIOPERATIVE STATIN THERAPY IN PATIENTS UNDERGOING ISOLATED VALVULAR HEART SURGERY: FIVE-YEAR SURGICAL EXPERIENCE (2010) (0)
- 33. Aspirin Resistance (2014) (0)
- SYSTEMATIC REVIEW OF PREVALENT AND INCIDENT HEART FAILURE IN CARDIOVASCULAR OUTCOME TRIALS OF PATIENTS WITH TYPE 2 DIABETES (2018) (0)
- PROGNOSTIC ROLE OF HEMOCONCENTRATION IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS OF THE EVEREST TRIAL (2013) (0)
- Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?☆ (2019) (0)
- RECLASSIFICATION OF HOSPITAL PERFORMANCE USING THE EXCESS DAYS IN ACUTE CARE MEASURE VS. 30-DAY READMISSIONS FOR HEART FAILURE AND ACUTE MYOCARDIAL INFARCTION: IMPLICATIONS FOR THE HOSPITAL READMISSIONS REDUCTION PROGRAM (2020) (0)
- Using antimatter to uncover what matters: metformin effects on myocardial efficiency in heart failure (2020) (0)
- Abstract 335: Association of Amyloidosis With In-hospital & 30-day Outcomes Among Patients Hospitalized With Heart Failure (2020) (0)
- Abstract 15507: Effect of Intensive Blood Pressure Control on Residual Lifespan in the SPRINT Trial (2019) (0)
- Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials. (2023) (0)
- Navigating Data Sharing in Cardiology From a Trainee's Perspective. (2018) (0)
- Personalizing Comprehensive Disease-Modifying Therapy: Obstacles and Opportunities. (2021) (0)
- Reply: Bounded Rationality and Clinical Guidance Documents for Heart Failure. (2022) (0)
- Application of a Medicare claims-based model predicting left ventricular ejection fraction subtype to investigate the epidemiology of heart failure in the US Medicare program (2020) (0)
- Abstract 19304: Clinical Profile and Outcomes of Patients Undergoing Combined Heart and Liver Transplantation With Transthyretin Amyloidosis: A Report From the International Consortium on Cardiac Amyloid Transplantation (iCCAT) (2015) (0)
- Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA (2020) (0)
- STALLED NATIONAL PROGRESS IN HEART FAILURE HOSPITALIZATIONS AMONG PATIENTS WITH DIABETES MELLITUS (2020) (0)
- HYPERKALEMIA AFTER HOSPITALIZATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: FINDINGS FROM THE ASTRONAUT TRIAL (2018) (0)
- Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease : the Systolic Blood Pressure Intervention Trial (2021) (0)
- Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus (2018) (0)
- DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE FOLLOWING SACUBITRIL/VALSARTAN INITIATION IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM PARAGON-HF AND PARADIGM-HF (2023) (0)
- Abstract 13645: Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction (2020) (0)
- Treatment Effects of Sacubitril/Valsartan Compared With Valsartan in Patients with Recent Hospitalization. (2021) (0)
- Abstract 12817: Comparison of New York Heart Association Classification and Patient-reported Outcomes Among Heart Failure Patients in U.S. Clinical Practice: CHAMP-HF (2020) (0)
- The Reply. (2018) (0)
- Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization? (2021) (0)
- Grim Messenger: Virchow's Node Presenting with Virchow's Triad. (2016) (0)
- The cardiovascular legacy of the COVID-19 pandemic. (2022) (0)
- Reply (2022) (0)
- Association of Readmission Penalty Amount with Subsequent 30-Day Risk Standardized Readmission and Mortality Rates Among Patients Hospitalized with Heart Failure: An Analysis of Get With The Guidelines - Heart Failure Participating Centers. (2021) (0)
- Prognostic implications of NYHA class and NT-proBNP levels in mild heart failure: a PARADIGM-HF analysis (2022) (0)
- Estimated Long-Term Bene fi t of Dapagli fl ozin in Patients With Heart Failure (0)
- Acute Cardiovascular Complications of COVID-19 (2023) (0)
- LEFT VENTRICULAR HYPERTROPHY AND SUBSEQUENT CARDIOVASCULAR RISK: DOES IT MATTER HOW IT IS DIAGNOSED? (2017) (0)
- Abstract 16327: Clinical Profiles, Care Patterns, Outcomes and Sex Differences of Patients With STEMI in India: Insights From the North Indian ST-segment Elevation Myocardial Infarction (NORIN STEMI) Registry (2020) (0)
- MISCLASSIFICATION OF MYOCARDIAL INJURY AS TYPE 2 MYOCARDIAL INFARCTION AND IMPLICATIONS FOR 30-DAY OUTCOMES (2019) (0)
- Influence of chronic kidney disease on warfarin therapy for atrial fibrillation. (2014) (0)
- Abstract 15734: Intersection of Atrial Fibrillation and Heart Failure With Mildly Reduced and Preserved Ejection Fraction in >400,000 Participants in the Get With the Guidelines® Heart Failure Registry (2022) (0)
- Systolic Blood Pressure, Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF (2020) (0)
- STATIN ELIGIBILITY PER CHOLESTEROL GUIDELINES PRIOR TO STEMI IN PATIENTS IN INDIA - THE NORTH INDIA ST-ELEVATION MYOCARDIAL INFARCTION REGISTRY (NORIN-STEMI) (2021) (0)
- Prognostic significance of polyvascular disease in patients admitted with acute decompensated heart failure: the ARIC Study Community Surveillance (2021) (0)
- 355-OR: WATCH-DM Identifies Diabetic Cardiomyopathy: A Multicohort Analysis (2022) (0)
- DIABETES RISK IN ADULTS WITH NORMAL WEIGHT IN THE UNITED STATES, 2013-2020 (2023) (0)
- Reply (2020) (0)
- What Looks Like a Clot But Is Not a Clot? (2020) (0)
- Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era-Reply. (2018) (0)
- NATRIURETIC PEPTIDES AS PREDICTIVE BIOMARKERS OF TREATMENT RESPONSE IN CLINICAL TRIALS OF HEART FAILURE (2018) (0)
- Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 Infection (2023) (0)
- Abstract 12208: Mode of Death in Heart Failure With Preserved Ejection Fraction: A Systematic Review (2016) (0)
- SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF (2020) (0)
- Reply Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients? (2020) (0)
- Hospitalized Heart Failure in the United States Learned from Clinical Trial (2015) (0)
- Feasibility of Virtual Optimization of Guideline Directed Medical Therapy in Hospitalized Patients with HFrEF During the Covid-19 Pandemic: The IMPLEMENT-HF Pilot Study (2020) (0)
- EFFECTS OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF (2022) (0)
- Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. (2023) (0)
- Considering dose in pharmacological therapies for heart failure – Authors' reply (2021) (0)
- and Mihai Gheorghiade Therapies Contemporary Drug Development in Heart Failure : Call for Hemodynamically Neutral (0)
- Abstract 18059: Clinical Profile and Prognostic Significance of Post-Discharge Hemodilution Among Patients Hospitalized for Heart Failure: Insights From the EVEREST Trial (2017) (0)
- Impact of Sex on Access to Donor Organs and Clinical Outcomes in the New 2018 US Adult Heart Allocation System - OPTN/UNOS Analysis (2021) (0)
- Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. (2020) (0)
- TCT-567 Cangrelor in Cardiogenic Shock: A Global, Multicenter, Matched Analysis with Oral P2Y12 Inhibition from the IABP-SHOCK II Trial (2018) (0)
- Abstract 11971: Gender Differences in Industry Payments Among Cardiologists (2019) (0)
- Clinical Investigations Trends in Heart Failure Clinical Trials From 2001e2012 (2016) (0)
- PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population (2023) (0)
- A rationale for dedicated trials of combination therapy in heart failure (2022) (0)
- Progn Scores Review Ferrero Int J Cardiol 2015 (2015) (0)
- Discovery and care innovation amidst a pandemic (2020) (0)
- Nonsteroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease. (2022) (0)
- Erratum: Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery (Journal of Thoracic and Cardiovascular Surgery (2010) 140 (1018-1027)) (2011) (0)
- The Enabling Potential of Device Therapy for Heart Failure. (2022) (0)
- Abstract 13820: Temporal Trends and Prognosis of Physical Exam Findings in Patients Hospitalized With Acute Decompensated Heart Failure With Preserved versus Reduced Ejection Fraction the Aric Study Community Surveillance (2020) (0)
- COST-EFFECTIVENESS OF SACUBITRIL-VALSARTAN IN CHRONIC HEART FAILURE AT EJECTION FRACTION RANGES BELOW NORMAL: A POOLED ANALYSIS FROM PARADIGM-HF AND PARAGON-HF. (2022) (0)
- NON-INFERIORITY DESIGNS OVER THE LAST DECADE OF CONTEMPORARY CARDIOVASCULAR CLINICAL TRIALS (2016) (0)
- Abstract 01: Association of Copayment Level and Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Adherence in Diabetes and Heart Failure (2023) (0)
- Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial (2023) (0)
- Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials (2022) (0)
- In Reply to Loh and Lin: (2014) (0)
- Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion (2021) (0)
- Race, Temporary Mechanical Circulatory Support, and Clinical Outcomes after the 2018 US Adult Heart Allocation System Policy Change (2021) (0)
- Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth. (2020) (0)
- Reply: Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNI. (2019) (0)
- Impact of COVID-19 on Heart Failure Clinical Trials (2023) (0)
- Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: decongesting the matter. (2015) (0)
- Potential Global Impact of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure. (2023) (0)
- Reporting cardiovascular clinical trials (2018) (0)
- Association of baseline and longitudinal changes in cardiometabolic health with risk of heart failure among adults with type 2 diabetes: an analysis from the Look AHEAD trial (2022) (0)
- Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. (2023) (0)
- 144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies (2020) (0)
- Natriuretic Peptide-Based Screening for Pre-Heart Failure in Patients With Type 2 Diabetes Across the United States. (2023) (0)
- GLYCEMIA, CORONARY MICROVASCULAR DYSFUNCTION AND CARDIOVASCULAR RISK (2020) (0)
- The Reply. (2018) (0)
- Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices (2019) (0)
- INFLUENCE OF URIC ACID LEVEL IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Electrocardiography and left ventricular function: looking beyond hypertrophy (2019) (0)
- HIGH-SENSITIVITY TROPONIN-T, LEFT VENTRICULAR SIZE AND FUNCTION, AND LONG-TERM OUTCOMES IN CLINICALLY STABLE, APPARENTLY HEALTHY OLDER SUBJECTS (2017) (0)
- Reply: effect of ivabradine on early readmissions after hospitalization for worsening heart failure. (2015) (0)
- ANGIOEDEMA WITH SACUBITRIL/VALSARTAN: TRIAL-LEVEL META-ANALYSIS OF OVER 15,000 PATIENTS & REAL-WORLD EVIDENCE TO DATE (2020) (0)
- Racial Disparities in Clinical Outcomes and Resource Utilization of Type 2 Myocardial Infarction in the United States: Insights from the National Inpatient Sample Database. (2022) (0)
- Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. (2016) (0)
- TEMPORAL TRENDS IN NON-CARDIOVASCULAR COMORBIDITIES AMONG PATIENTS HOSPITALIZED WITH ACUTE VS CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE ARIC STUDY (2021) (0)
- Serial high-sensitivity troponin T concentrations and long-term outcomes in patients with suspected acute coronary syndrome (2022) (0)
- Abstract 209: Prevalence and Prognostic Significance of Aortic Stenosis in Patients With Acute Decompensated Heart Failure: The Atherosclerosis Risk in Communities Study (2020) (0)
- 2019-06-01 Wake Forest University long-term follow-up of type 2 myocardial infarction : The Wake-Up T 2 MI Registry (2019) (0)
- Modifiable Risk Factor Burden Among 3 Different Age Groups with Heart Failure. (2021) (0)
- Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. (2023) (0)
- Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials (2018) (0)
- Abstract 12845: Renal Biomarkers Predict Long-Term Adverse Events in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial (2016) (0)
- The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. (2013) (0)
- MID-LIFE WEALTH MOBILITY AND LONG-TERM CARDIOVASCULAR HEALTH - THE HEALTH AND RETIREMENT SURVEY (2021) (0)
- Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials: Inconsistent Outcome Reporting in HF RCTs. (2022) (0)
- Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial (2022) (0)
- Wednesday, 29 August 2012 (2012) (0)
- 4877Renal function and intensive blood pressure lowering in high-risk adults without diabetes: insights from the Systolic Blood Pressure Intervention Trial (SPRINT) (2019) (0)
- Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial (2017) (0)
- Contents Vol. 125, 2013 (2013) (0)
- Abstract 16749: Prevalence, Predictors, and Prognostic Implications of Left Ventricular Systolic Dysfunction Among Patients With STEMI in India: The Prospective NORIN-STEMI Registry (2020) (0)
- Value-based care in cardiology: warranty periods. (2014) (0)
- MINERALOCORTICOID RECEPTOR ANTAGONISTS IN DIABETIC PATIENTS HOSPITALIZED WITH HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure. (2021) (0)
- Reply (2020) (0)
- SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- CARDIAC REHABILITATION FOR TYPE 2 MYOCARDIAL INFARCTION (2019) (0)
- Reply: Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. (2020) (0)
- PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF MITRAL REGURGITATION IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY (2020) (0)
- Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial (2021) (0)
- IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS (2017) (0)
- TEMPORAL TRENDS IN SEVERITY IN CLINICAL RISK PROFILES AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE (2020) (0)
- TWENTY-EIGHT YEAR TRENDS IN ACUTE MYOCARDIAL INFARCTION WITH INPATIENT-ONSET: THE ATHEROSCLEROSIS RISK IN COMMUNITIES SURVEILLANCE STUDY, 1987-2014 (2019) (0)
- Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial (2023) (0)
- Abstract 21161: Use of an Open Access Multi-Sponsor Data Sharing Platform in Cardiology (2017) (0)
- Donor Diabetes Mellitus Status and Contemporary Outcomes After Cardiac Transplantation. (2023) (0)
- VARIABILITY IN RESPONSE TO PRASUGREL AND TICAGRELOR OVER TIME IN PATIENTS WITH ACUTE CORONARY SYNDROME (2014) (0)
- Heart Failure Specific Versus All-Cause Endpoints in Heart Failure Clinical Trials. (2022) (0)
- Death from Munchausen syndrome : A case of idiopathic recurrent right ventricular failure and a review of the literature Running Title : Fatalities from Munchausen Syndrome (2014) (0)
- RISK FACTORS AND OUTCOMES OF YOUNG ADULTS WHO EXPERIENCE MYOCARDIAL INFARCTION: INSIGHTS FROM THE NORIN-STEMI REGISTRY (2021) (0)
- In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor (2022) (0)
- Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. (2020) (0)
- Abstract 13445: Patterns and Outcomes of Thoracic Organ Transplantation Across Citizenship Status in the United Status (2020) (0)
- P57262018 ESC/ESH guideline-recommended age categories and intensive blood pressure management in high-risk adults: insights from SPRINT (2019) (0)
- Functional assessment based on cardiopulmonary exercise testing in mild heart failure: A multicentre study. (2023) (0)
- Genetic variation in sodium glucose co‐transporter 1 and cardiac structure and function at middle age (2022) (0)
- Sudden Flare of Rheumatoid Arthritis Associated with Newly Diagnosed Atrial Flutter (2014) (0)
- 316-OR: Diabetes Care among Older Adults Enrolled in Medicare Advantage vs. Traditional Medicare Fee-for-Service Plans: The Diabetes Collaborative Registry (2021) (0)
- 419Body mass index and intensive blood pressure management in high-risk adults: insights from the systolic blood pressure intervention trial SPRINT) (2018) (0)
- Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME (2020) (0)
- Missed Opportunities for Screening and Management of Dysglycemia among Patients Presenting with Acute Myocardial Infarction in North India: The Prospective NORIN STEMI Registry (2022) (0)
- Improving outcomes in cardio-renal-metabolic diseases. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Muthiah Vaduganathan?
Muthiah Vaduganathan is affiliated with the following schools:
